Announces First Human Case for V-Sono(TM) Module
ST. LOUIS, -- Stereotaxis, Inc. (NASDAQ: STXS) today announced that the Company has released to the European market the V-Sono(TM) intracardiac echocardiography manipulator module for the Vdrive(TM) Remote Navigation System.
Designed to manipulate accessory devices such as variable loop catheters, steerable sheaths, and ultrasound catheters, the Vdrive(TM) platform combines magnetic navigation with the Odyssey(TM) information management system to bring precise control during catheter-based EP procedures.
The Company also announced the first human case using the V-Sono(TM) module has been performed by Dr. Georg Nolker of Herz und Diabeteszentrum Klinik fur Kardiologie in Bad Oeynhausen, Germany on April 30, 2012. A patient was treated for a complex left persistent atrial fibrillation and Dr. Nolker performed a fully remote intervention, using the Vdrive Duo(TM) platform (the V-Loop(TM) module for the circular mapping catheter and the V-Sono(TM) module for the ICE catheter) in concert with the Niobe® ES Magnetic Navigation System.
Dr. Nolker said, "Intracardiac Echo has been long established to provide patient safety and cardiac visualization without radiation. This new robotic control makes intracardiac echo more stable, precise, and easier to use in a way that has not been previously available."
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey(TM) portfolio of lab optimization, networking and patient information management systems and the Vdrive(TM) Robotic Mechanical Navigation system and consumables.
The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop(TM) circular mapping catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.
CONTACT: Sam Duggan, Chief Financial Officer of Stereotaxis, Inc., +1-314-678-6007; or Investors, Gregory Gin, +1-646-445-4801, or Robert Jones, +1-646 201-5447, both of EVC Group, Inc., for Stereotaxis, Inc.; or Media, Frank Cheng, Senior Vice President, Marketing & Business Development of Stereotaxis, Inc., +1-314-678-6111
Web Site: www.stereotaxis.com